Cargando…
Type I interferon/IRF7 axis instigates chemotherapy-induced immunological dormancy in breast cancer
Neoadjuvant and adjuvant chemotherapies provide survival benefits to breast cancer patients, in particular in estrogen receptor negative (ER(−)) cancers, by reducing rates of recurrences. It is assumed that the benefits of (neo)adjuvant chemotherapy are due to the killing of disseminated, residual c...
Autores principales: | Lan, Qiang, Peyvandi, Sanam, Duffey, Nathalie, Huang, Yu-Ting, Barras, David, Held, Werner, Richard, François, Delorenzi, Mauro, Sotiriou, Christos, Desmedt, Christine, Lorusso, Girieca, Rüegg, Curzio |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Nature Publishing Group UK
2018
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6477891/ https://www.ncbi.nlm.nih.gov/pubmed/30546090 http://dx.doi.org/10.1038/s41388-018-0624-2 |
Ejemplares similares
-
Dormant Tumor Cell Vaccination: A Mathematical Model of Immunological Dormancy in Triple-Negative Breast Cancer
por: Mehdizadeh, Reza, et al.
Publicado: (2021) -
The matricellular protein CYR61 promotes breast cancer lung metastasis by facilitating tumor cell extravasation and suppressing anoikis
por: Huang, Yu-Ting, et al.
Publicado: (2016) -
Targeting the Extra-Cellular Matrix—Tumor Cell Crosstalk for Anti-Cancer Therapy: Emerging Alternatives to Integrin Inhibitors
por: Lorusso, Girieca, et al.
Publicado: (2020) -
Late effects of adjuvant chemotherapy adumbrate dormancy complexity in breast cancer
por: Demicheli, Romano, et al.
Publicado: (2020) -
Targeting myeloid-derived suppressor cells in combination with tumor cell vaccination predicts anti-tumor immunity and breast cancer dormancy: an in silico experiment
por: Mehdizadeh, Reza, et al.
Publicado: (2023)